TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients \>=18 years of age;~* untreated ITP.~Exclusion Criteria:~* ITP with relapse;~* positive test result for HIV or hepatitis B or C;~* active infection requiring systemic therapy;~* malignancy within 3 years before study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: ACTIVE_COMPARATOR): Participants received 40 milligrams (mg) dexamethasone, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4). Participants in this treatment arm who failed to achieve a sustained response and had a platelet count of less than or equal to (≤)20 x 10\^9 platelets per liter (L; from Day 30 up to end of 6 months) were treated with salvage treatment of dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg per square meter (mg/m\^2), intravenously (IV), with premedication of oral acetaminophen 500 mg and chlorpheniramine 10 mg IV on Days 7, 14, 21, and 28.
- Dexamethasone plus Rituximab (Type: EXPERIMENTAL): Participants received dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m\^2, IV, with premedication of oral acetaminophen 500 mg and chlorpheniramine 10 mg IV on Days 7, 14, 21, and 28. Nonresponsive participants with platelets less than (\<) 20 x10\^9/L or with active bleeding could have also received an additional treatment course of dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m\^2, IV on Days 7, 14, 21, and 28 administered with immunoglobulin (IgG) IV (at investigator discretion) and/or low/medium dose steroids (at investigator discretion) on Days 7, 14, 21, and 28.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PCP Use of a Gene Expression Test (Corus CAD or ASGES) in Coronary Artery Disease Diagnosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Stable chest pain, typical or atypical angina or anginal equivalent~2. The patient has signed the appropriate Institutional Review Board approved Informed Consent Form.~Exclusion Criteria:~1. History of myocardial infarction~2. Current Myocardial infarction (MI) or acute coronary syndrome.~3. Current New York Heart Association (NYHA) class III or IV congestive heart failure symptoms.~4. Any previous coronary revascularization.~5. Any individuals with :~   * Diabetes~  * Suspected unstable angina~  * Systemic infections~  * Systemic inflammatory conditions~6. Any individuals currently taking:~   * Steroids~  * Immunosuppressive agents~  * Chemotherapeutic agents~7. Any Major Surgery within 2 months

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All subjects (Type: None): Subjects are enrolled at multiple participating primary care practices. The main inclusion criterion for enrollment is the occurrence of chest pain (or anginal equivalent) in a patient without known significant coronary artery disease (CAD) or a history of prior myocardial infarction.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 6 months to 12 years~* ear tube in the ear which will be treated~* otorrhea for 3 weeks or less~* moderate or severe otorrhea~Exclusion Criteria:~* other ear diseases

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- DF289 (Type: ACTIVE_COMPARATOR): Ear drops
- DF277 (Type: ACTIVE_COMPARATOR): Ear drops
- DF289 plus DF277 (Type: EXPERIMENTAL): Ear drops

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma,~* Ages \>/= 1 and \</= to 30 years at the time of initial diagnosis~* Undergoing asparaginase treatment for ALL or lymphoblastic lymphoma~* Documented Grade 2 or higher hypersensitivity reaction to native or pegylated E. coli asparaginase or Calaspargase pegol~* Must have two remaining weeks of native E. coli asparaginase treatment or 1 remaining dose of either Pegaspargase or Calaspargase pegol~* Direct bilirubin less than or equal to Grade 2~* Amylase and lipase within normal limits (per institutional standards)~* Signed informed consent by the patient is greater than or equal to 18 years or by the parent if the patient is younger than 18 years old.~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Open-Label Erwinaze (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chloroquine for Treatment of Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Tumor restricted to one hemisphere of the brain~* Karnofsky scale \>7~* Histologically confirmed GBM in first or second recurrence or relapse~* Adequate hematologic, hepatic and renal function~* Karnofsky performance status score ≥ 70%~* Life expectancy ≥ 16 weeks~Exclusion Criteria:~* Gastrointestinal dysfunction~* Compromised cardiac function~* Concurrent severe and /or uncontrolled medical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anidulafungin In Treatment Of Candidemia In Asian Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with at least one positive blood test for Candida pathogen from a blood sample taken within 96 hours prior to start of study treatment.~* Subjects with clinical evidence of candida infection within 48 hours prior to enrollment.~* Acute Physiology and Chronic Health Enquiry (APACHE) score less than or equal to 20.~Exclusion Criteria:~* Prior exposure to systemic antifungals for more than 48 hours.~* Subjects who had, at any time, previously received anidulafungin.~* Subjects with poor venous (vein) access that would inhibit the administration of the intravenous study drug or withdrawing of multiple blood samples.~* Life expectancy \< 72 hours.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open (Type: OTHER): This is an open-label, multi-center, non-comparative 12 week study evaluating the efficacy and safety of anidulafungin in subjects with candidemia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Two Dosages of Diractin® in Osteoarthritis (OA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent signed and dated~* Age \> 45 years~* Class I-III OA of the knee and subject meets American College of Rheumatology (ACR) clinical classification criteria for osteoarthritis of the knee~Exclusion Criteria:~* Skin lesions or dermatological diseases in the treatment area~* Directly or indirectly involved in the conduct and administration of this study~* Received any investigational medicinal product within 30 days prior to Screening Visit or participation in any previous clinical study with Diractin®~* Pregnancy or lactation~* Residents of psychiatric wards, prisons or other state institutions~* Malignancy within the past 2 years~* Depressive disorders requiring treatment with tricyclics, treatment with other antidepressants must be stable for 3 months prior to screening and throughout the study~* Epilepsy~* Schizophrenia~* Neuropathic pain and any other pain condition requiring chronic use of pain medication~* Known hypersensitivity or allergy (including photoallergy) to NSAID´s including ketoprofen, celecoxib, sulfonamides and ingredients used in pharmaceutical products including galactose~* Peripheral arterial disease and/or cerebrovascular disease~* History of stroke or myocardial infarction~* Congestive Heart failure NYHA Class II-IV~* History of pancreatitis or peptic ulcers;~* Inflammatory GI disease (e.g. M. Crohn, colitis ulcerosa)~* Serum creatinine levels \> 2.5 milligrams/deciliter (mg/dL)~* ALT or AST levels ≥ 5 times the ULN~* Unable to discontinue analgesic therapy including opioids, NSAID´s, tramadol, muscle relaxants, gabapentin, pregabalin, duloxetine, venlafaxine, capsaicine or other drugs approved or used for the treatment of pain for the duration of the study

- Gender: ALL
- Minimum Age: 46 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: ACTIVE_COMPARATOR): None
- 4 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects 12 years of age or older~* acne vulgaris with facial involvement~* A score of 3 (Moderate) or 4 (Severe) on the Investigator's Global Assessment Scale (inflammatory)~* 25 to 75 inflammatory lesions (papules and pustules) on the face (including the nose)~Exclusion Criteria:~* More than two acne nodules/cysts on the face~* Acne conglobata, acne fulminans, secondary acne (chloracne, drug induced acne, etc.), or severe acne requiring systemic retinoid treatment~* Underlying diseases or other dermatologic conditions that require the use of interfering topical or systemic therapy such as, but not limited to, atopic dermatitis, perioral dermatitis or rosacea~* Beard or facial hair which might interfere with study assessments~* planning excessive exposure to sun or ultraviolet light during the study (i.e. natural or artificial sunlight, including tanning booths and sun lamp)~* Use of oral contraceptives solely for control of acne~* Liver function test alanine transaminase (ALT) and/or aspartate transaminase (AST) 2.5 times above upper limit of normal~* Renal function test serum creatinine at 150 umol/L (17 mg/L) or higher~* Presence of oral or genital candidiasis or history of multiple episodes of oral or genital candidiasis~* Females who intend to conceive a child within 5 months following Baseline visit~* Males who intend to conceive a child with partner during the study period~* Requiring concomitant use of methoxyflurane

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CD2475/101 40 mg (Type: EXPERIMENTAL): Participants receive 40 mg of CD2475/101 oral tablet plus placebo capsule orally once daily for 16 weeks.
- Doxycycline 100 mg (Type: ACTIVE_COMPARATOR): Participants receive 100 mg of Doxycycline capsule plus placebo tablet orally once daily for 16 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive matching placebo tablet plus placebo capsule orally once daily for 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.~* A male or female adult who received the complete neonatal primary vaccination course of hepatitis B vaccine in primary study approximately 20 years earlier.~* Documented level of anti-HBs antibody concentrations \< specified concentration at the previous long-term time point for which serological results are available for that subject.~* Written informed consent obtained from the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* If the subject is female, she must be of non-childbearing potential or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the hepatitis B challenge dose.~Exclusion Criteria:~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the hepatitis B vaccine challenge dose.~* Administration of a vaccine not foreseen by the study protocol during the study period.~* Administration of immunoglobulins and/or any blood products during the study period.~* Drug and/or alcohol abuse.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 21 Years
- Healthy Volunteers: t

Study Arms:
- Group Engerix™-B (Type: EXPERIMENTAL): Subjects received a dose of Hepatitis B vaccine approximately 20 years after the primary neonatal vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects with type-II diabetes mellitus;~2. Subjects aged between 20 and 80;~3. Subjects whose HbA1c ratio is between 7.0% and 10.0%;~4. Subjects who took Metformin and Sitagliptin for at least 12 weeks;~5. Subjects who were given the explanation about this clinical study and signed the consent form.~Exclusion Criteria:~1. Subjects who have taken drugs that are likely to affect blood glucose or who need to take such drugs, e.g., glucocorticoid;~2. Subjects with severe renal diseases (men: Scr\>1.5 / women: Scr\>1.4);~3. Subjects with severe liver diseases or whose AST and ALT are at least 2.5 times higher than the upper limits of normal (ULN);~4. Subjects having the case history of lactic acidosis;~5. Subjects who have the case history of myocardial infarction or unstable angina or who underwent the coronary artery bypass graft 6 months before the screening test or who have arrhythmia to be treated;~6. Subjects with congestive heart failures to be treated;~7. Subjects who fall into New York Heart Association (NYHA) class III or IV;~8. Subjects having the case history of acute or chronic metabolic acidosis including ketoacidosis;~9. Subjects who have been pregnant or who are in the period of lactation;~10. Subjects diagnosed with malignant tumors within 5 years;~11. Subjects who are hypersensitive to Metformin, Sitagliptin and Acarbose or their ingredients;~12. Subjects with inflammatory bowel diseases or intestinal ulcers or enterostenosis (includes Subjects who are vulnerable to enterostenosis) or chronic enteric diseases related to digestion and absorption or whose symptoms are likely to worsen due to intestinal gas;~13. Subjects who participated in other clinical studies as Subjects within 60 days before this study (or before taking the investigational drugs);~14. Subjects judged unfit for this study by investigators.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Acarbose placebo, Metformin, Sitagliptin (Type: PLACEBO_COMPARATOR): The Acarbose placebo should be changed into real Acarbose from the 16th week.
- Sitagliptin, Metformin, Acarbose (Type: EXPERIMENTAL): Metformin, Sitagliptin, Acarbose group
- Metformin placebo, Sitagliptin, Acarbose (Type: OTHER): The Metformin placebo should be changed into real Metformin from the 16th week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Sleep-maintenance Activity of 3 Doses of SKP-1041

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Primary insomnia characterized by chronic difficulty maintaining sleep~Exclusion Criteria:~* History of restless legs syndrome, sleep apnea, narcolepsy, or parasomnias;~* Any clinically relevant acute or chronic diseases which could interfere with the patient's safety during this trial or with this tablet's absorption;~* Pregnancy;~* History of medication allergies;~* Use of medication that might interfere with this study;~* Recent travel across more than 3 time zones.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Two placebo tablets administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
- 10 mg SKP-1041 (Type: EXPERIMENTAL): One 10 mg SKP-1041 controlled release zaleplon tablet plus one placebo tablet administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
- 15 mg SKP-1041 (Type: EXPERIMENTAL): One 15 mg SKP-1041 controlled release zaleplon tablet plus one placebo tablet administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
- 20 mg SKP-1041 (Type: EXPERIMENTAL): Two 10 mg SKP-1041 controlled release zaleplon tablets administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: the TESTsmART Trial AIM 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with fever or history of fever or malaria like illness~* Individual with malaria-like illness must be present at recruitment~* 1 year of age or older~Exclusion Criteria:~* Any individual with signs of severe illness requiring immediate referral~* Individuals who have taken an antimalarial in the last seven days, including for the current illness~* Individuals who already have a prescription from a facility or medical provider~* Pregnant women will be enrolled and offered an mRDT, but will be advised to seek treatment through a health care provider.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): The subsidy levels for participants randomly assigned to Arm 1 are: No subsidy for RDT (price to consumer=$0.40); 100% ACT subsidy (price to consumer=0).
- Arm 2 (Type: EXPERIMENTAL): The subsidy levels for participants randomly assigned to Arm 2 are: No subsidy for RDT (price to consumer=$0.40); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age).
- Arm 3 (Type: EXPERIMENTAL): The subsidy levels for participants randomly assigned to Arm 3 are: 50% subsidy for RDT (price to consumer=$0.20); 100% ACT subsidy (price to consumer=0).
- Arm 4 (Type: EXPERIMENTAL): The subsidy levels for participants randomly assigned to Arm 4 are: 50% subsidy for RDT (price to consumer=$0.20); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete